Product Overview
Medium-chain triglycerides (MCT) are a mixture of triglycerides formed through the esterification reaction of caprylic and capric saturated fatty acids with glycerol. They appear as a colorless to slightly yellow, clear oily liquid and are a mainstream pharmaceutical-grade lipid raw material. This product is manufactured by Baiyunshan Hanfang, with CDE registration number Y20200001227 (Status A). It meets the triple quality standards of the Chinese Pharmacopoeia CP, the United States Pharmacopeia USP, and the European Pharmacopoeia EP. It is widely used in the production of various fat emulsions, soft capsules, eye drops, and other pharmaceutical products, serving both as a carrier for lipophilic drugs and as a source of essential fatty acids to rapidly supply energy. MCT is metabolized quickly and completely in the human body, without imposing an additional metabolic burden on the liver or immune system, making it a core oil-phase ingredient for formulation development and large-scale production in the pharmaceutical industry.
Working Principle
As an oil-phase ingredient, medium-chain triglycerides are added to various formulation recipes, leveraging their inherent lipophilicity to encapsulate poorly soluble active pharmaceutical ingredients, ensuring uniform dispersion. Once inside the human body, unlike long-chain fats, MCT follows a shorter metabolic pathway, undergoing rapid breakdown and absorption, quickly hydrolyzing to provide energy and replenishing essential fatty acids. The raw material strictly controls impurity levels, free from harmful contaminants that could interfere with organ function or impose metabolic stress on the liver and immune system, thus meeting the stringent safety requirements for both injectable and oral pharmaceutical products.
Core Advantages and Selling Points
Compliant with multiple pharmacopoeias and universally accepted in global markets: This product meets the rigorous standards of the Chinese Pharmacopoeia ChP, the United States Pharmacopeia USP, and the European Pharmacopoeia EP, possessing complete compliance certifications. It can directly access pharmaceutical markets in numerous countries worldwide, reducing customers’ costs associated with export compliance reviews.
High-standard safety control and outstanding pharmaceutical safety: Elemental impurities are managed in accordance with ICH Q3D guidelines; it contains no substances posing TSE/BSE risks, nor does it harbor genotoxic impurities such as benzo[a]pyrene or aflatoxins. Organic solvents are entirely excluded from the manufacturing process, effectively preventing potential safety hazards in finished formulations.
Excellent physicochemical properties and superior storage stability: With low oxidation indicators and strong lipid stability, this product resists oxidative rancidity, ensuring long-term shelf life for finished formulations.
Customizable specifications to suit diverse formulations: We can tailor higher internal control standard specifications according to clients’ R&D and mass-production needs, flexibly adapting to different dosage forms such as fat emulsions, soft capsules, and eye drops.
Human-body-friendly metabolism and significant advantages in formulation applications: MCT is metabolized rapidly and completely within the human body, placing no metabolic burden on the liver or immune system, thereby greatly enhancing the clinical safety of fat emulsion injections.
Target Customer Groups
Pharmaceutical companies producing medicinal fat emulsions, research institutes engaged in pharmaceutical formulation development, manufacturers of soft capsules, producers of veterinary medicines, purchasers of raw materials for eye drops, and overseas traders involved in the import and export of pharmaceutical raw materials.
Application Scenarios
Production of nutritional fat emulsions: Medium- and long-chain fat emulsion injections, various oil-based fat emulsion injections, medium- and long-chain fat emulsion/amino acid/glucose injection formulations, and raw material supplies for ω-3 fish oil series composite fat emulsion injections.
Production of drug-loaded intravenous fat emulsions: Propofol medium-chain fat emulsion injections, etomidate medium- and long-chain fat emulsion injection carriers.
Other pharmaceutical formulation areas: Medicinal medium-chain triglyceride soft capsules, raw materials for medical eye drops, and oil-phase carriers for various veterinary animal medicines.
Solving Industry Pain Points
Addresses the issue of conventional lipid raw materials having single pharmacopoeial qualifications and being unable to meet export requirements in multiple markets; overcomes the problem of lax impurity control in standard lipids, which often contain genotoxic substances and TSE/BSE-related risks, failing to satisfy the strict standards required for injectable medications; improves the situation where high oxidation values and susceptibility to spoilage lead to poor stability and short shelf lives of finished formulations; and avoids the shortcomings of certain raw materials containing residual organic solvents that do not comply with pharmaceutical-grade injection regulations.
Core Product Value
Baiyunshan Hanfang’s medicinal medium-chain triglycerides, backed by comprehensive compliance certifications and stringent quality-control systems, help pharmaceutical companies save on repeated testing and qualification application costs across multiple pharmacopoeias; high-standard impurity control reduces the risk of adverse clinical reactions and minimizes post-sales losses; excellent antioxidant performance decreases storage losses and lowers the rate of scrapped finished products; customizable specifications accommodate differentiated formulation needs, shortening new-product R&D cycles and supporting pharmaceutical companies in smoothly completing domestic and international registrations and commercial launches of various fat emulsions and oral formulations.
Common Questions FAQ
Q1: Does this medium-chain triglyceride have CDE registration?
A: Baiyunshan Hanfang’s product has CDE registration number Y20200001227, with registration status A.
Q2: Which pharmacopoeial standards does this product comply with?
A: This product simultaneously meets the quality standards of the Chinese Pharmacopoeia CP, the United States Pharmacopeia USP, and the European Pharmacopoeia EP.
Q3: What advantages does MCT offer in human metabolism?
A: It is metabolized rapidly and completely within the human body, without imposing any metabolic burden on the liver or immune system, making it ideal for preparing intravenous fat emulsions.
Q4: In what ways is the raw material’s safety demonstrated?
A: It adheres to ICH Q3D elemental impurity standards, poses no TSE/BSE risks, contains no benzo[a]pyrene or aflatoxins, and is produced entirely without the use of organic solvents.
Q5: Can special-specification medium-chain triglycerides be customized?
A: Customization of higher internal control standard specifications is supported, catering to the production of fat emulsions, soft capsules, eye drops, and other formulation types.
